CBI’s 4th Annual Compliance Congress for Specialty Products

CBI’s 4th Annual Compliance Congress for Specialty Products
September 13-14, 2018 | Boston, MA
www.cbinet.com/specialtycompliance

CBI’s 4th Annual Compliance Congress for Specialty Products explores the unique compliance challenges for specialty bio/pharmaceutical companies, pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for manufacturers. A comprehensive compliance program is essential to correctly assessing risks, including patient assistance programs, non-commercial activities, third-party relationships and pharmacy contracting.

At this meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Register by 7/27/2018 and receive $400* off the standard rate with discount code SPC400.

Valuable Insights from 35+ Thought Leaders, Including:

• Gregg Shapiro, Assistant U.S Attorney, Chief of Affirmative Civil Enforcement Unit, U.S Department of Justice (Boston)
• Charles Graybow, Assistant U.S. Attorney, U.S. Attorney's Office, District of New Jersey
• Bill Hrubes, Vice President, Chief Compliance Officer, ACell, Inc.
• Shoshanna Clark, Head of Operations, NA Ethics & Business Integrity, Sanofi
• Alessandra Ravetti, Executive Director and Assistant General Counsel, Regeneron Pharmaceuticals, Inc.
• Trish Shorey, Privacy Officer, Global Compliance and Risk Management, Shire
• Heidy Abreu, Vice President, Legal and Corporate Secretary, Axcella Health, Inc.
• Kelly Pitt, Director, Legal & Compliance, Sobi, Inc.
• Amy Wilson, MBA, MSJ, Director, Enterprise Compliance, Alexion Pharmaceuticals
• Alessandro Martuscelli, Chief Global Therapeutics Counsel, Bioverativ
• Chad Morin, Senior Director, Healthcare Compliance, bluebird bio
• Brian Conner, Vice President, Head of Corporate Compliance, Strongbridge Biopharma plc
• Sarah Whipple, Senior Corporate and Compliance Counsel, Akebia Therapeutics, Inc.
• David Ryan, Vice President, Associate General Counsel, Chief Compliance Officer, Haemonetics Corporation

Key Reasons to Attend:

• Create a balance between effective patient assistance programs and maintaining compliant practices
• Address the legal issues related to “proactive” versus “reactive” presentations around disease state
• Gain insight into operational safeguards around copay assistance and charitable donations
• Determine if a nurse educator program is necessary and where it should sit within the organization
• Review current and pending state transparency and disclosure legislation
• Assess the controls that compliance or legal need to put in place to ensure that value-based agreements comply with the Anti-Kickback Statute
• Examine the changes in E.U. privacy laws and discuss why it matters to U.S. companies

Register by 7/27/2018 and receive $400* off the standard rate with discount code SPC400.

*Offer expires July 27, 2018; applies to standard rates only and may not be combined with other offers, category rates, and promotions or applied to an existing registration.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.